Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough...
Read More Details
Finally We wish PressBee provided you with enough information of ( Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough )
Also on site :
- 'SNL' Icons Reunite With Boss Lorne Michaels For Prestigious Award
- America’s first zoning law was about race
- I’m a Celebrity Dermatologist in My 60s and Here’s My 5-Minute Skincare Routine